CLChristopher E. Lominska

Christopher E. Lominska

*This is an algorithmically generated author record based on publicly available information.

Christopher E. Lominska has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Logistic Model in Clinical and Health Research—the Elephant and Blind Men

    by Ying Cao, Aaron J. Katz, Xinglei Shen, Ryan T. Morse, Christopher E. Lominska, Ronald C. Chen

    Logistic models are everywhere in scientific research, including clinical and health research. However, there is no practical report on research results that will utilize many available statistical tools but mostly 1 or 2 only, for a logistic model. We introduce 6 powerful statistical tools, forest plot, AUC curve, nomogram, and decision curve analysis, as well as bootstrapping sampling and cross validation, by applying head and neck cancer data to a logistic model. We hope that these tools will make the logistic model, and accordingly our research, more comprehensive and clinically more applicable. In the 6 parts of the article, we introduce each of the 6 statistical tools (methods) with relevant figures and interpretations on key statistical concepts to show how we can improve our understanding on the logistic model and the clinical prospects behind the data. The statistical tools we present in the current special communication for reporting research or clinical trials in a logistic model, if popularized among researchers and clinicians, will make a research conclusion more comprehensive, valid and clinically applicable to other cases.

  • Open Access

    Sarcopenia and Treatment Toxicity in Older Adults Undergoing Chemoradiation for Head and Neck Cancer: Identifying Factors to Predict Frailty

    by Ryan T. Morse, Rohit G. Ganju, Gregory N. Gan, Ying Cao, Prakash Neupane, Kiran Kakarala, Yelizaveta Shnayder, Christopher E. Lominska

    This study was performed to identify treatment related toxicities in older adults undergoing concurrent chemoradiotherapy for head and neck cancer and nutritional and skeletal muscle measures that might identify frailty. Imaging analysis was done with the following skeletal muscle measurements: skeletal muscle index (SMI), skeletal muscle density (SMD), and skeletal muscle gauge (SMG). Patients were dichotomized by age into younger (p < 0.01), as were low SMD (57.8% vs. 37.3%, p = 0.012) and low SMG (76.1% vs. 44.2%, p < 0.01), despite having similar BMIs (27.3 kg/m2 versus 27.7 kg/m2, p = 0.71). Older patients were significantly more likely to experience chemotherapy toxicity than younger patients (54.9% versus 32.3%, p < 0.01). On multivariate analysis age (p < 0.01), current smoking status (p < 0.01), and low SMI (p < 0.01) remained as significant predictors for missed chemotherapy cycles or discontinuation. Older patients were more likely to require ≥5-day radiation breaks than younger patients (27.5% versus 8.6%, p < 0.01). On multivariate analysis, age (p < 0.01), low albumin status (p = 0.03), and low SMI (p = 0.04) were identified as predictors of prolonged radiation treatment breaks. Based on the results of our study, sarcopenia may be used as an additional marker for frailty alongside traditional performance status scales.


  • Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma

    by Ryan T. Morse, Rohit G. Ganju, Mindi J. TenNapel, Prakash Neupane, Kiran Kakarala, Yelizaveta Shnayder, Allen M. Chen, Christopher E. Lominska

    Background: Triweekly high‐dose cisplatin (100 mg/m2) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m2 with alternative weekly 40 mg/m2 and weekly 2 cisplatin regimens.Methods: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity‐modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression‐free survival.Results: Cisplatin weekly 2 showed inferior OS outcomes when compared to weekly 40 mg/m2 (P = 0.084) and triweekly 100 mg/m2 (P = 0.04) regimens.Conclusion: Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m2, suggesting the inferiority of low‐dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m2 chemotherapy regimens.


  • Open Access

    CASTLE Thyroid Tumor: A Case Report and Literature Review

    by Chris Lominska, Christopher Fleighton Estes, Prakash C. Neupane, Y. Shnayder, Mindi J. TenNapel, Maura F. O’nEil

    Carcinoma showing thymus like differentiation is a rare tumor of the thyroid gland which is structurally similar to thymic tissue. Overall, it has a favorable prognosis. Radiotherapy has been shown to be an effective local treatment, but there have been reports of distant recurrence. It has been suggested that adding chemotherapy may decrease the risk of recurrence. Here, we present a case report of a patient with a large tumor and extrathyroidal extension. The patient was treated with surgery, radiotherapy, and cisplatin with acceptable toxicity. The patient is free of locally recurrent or distant disease at 3 years.


  • Open Access

    Stereotactic Body Radiotherapy for Treatment of Squamous Cell Carcinoma of the Tongue Associated with Human Papilloma Virus: A Case Report

    by Brian Rodgers, Prakash Neupane, Chris Lominska, Yelizaveta Shnayder

    Stereotactic body radiotherapy (SBRT) has emerged as a treatment for recurrent squamous cell carcinoma of the head and neck in the field of prior radiation. We report a case of its use in an human papilloma virus (HPV) positive patient with squamous cell carcinoma of the right base of tongue. The patient had complete response to treatment and modest toxicities were noted. This represents encouraging results that SBRT is also useful for salvage in patients with HPV positive disease.


  • Open Access

    Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas

    by Chris E Lominska, Keith Unger, Nadim M Nasr, Nadim Haddad, Greg Gagnon

    Local control rates are poor in the treatment of pancreatic cancer. We investigated the role of hypofractionated stereotactic body radiation therapy (SBRT) for salvage or boost treatment after conventional doses of external beam radiation therapy.